LON:RENEReNeuron Group Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ReNeuron Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 142.50 +2.50 (+1.79 %) (As of 07/10/2020 02:29 PM ET) Add Compare Share Today's Range 142.50Now: GBX 142.50▼ 145.0650-Day Range 125MA: GBX 139.16▼ 15152-Week Range 71Now: GBX 142.50▼ 297.50Volume14,977 shsAverage Volume28,700 shsMarket Capitalization£45.36 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ReNeuron Group. Previous Next 3.0 Community Rank Outperform VotesReNeuron Group has received 187 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReNeuron Group has received 121 “underperform” votes. (Add your “underperform” vote.)Community SentimentReNeuron Group has received 60.71% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote “Outperform” if you believe RENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReNeuron Group does not currently pay a dividend.Dividend GrowthReNeuron Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ReNeuron Group insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ReNeuron Group are expected to grow in the coming year, from GBX (81.40) to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ReNeuron Group is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ReNeuron Group is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReNeuron Group has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.73 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:RENE Previous Symbol CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400Debt Debt-to-Equity Ratio4.69 Current Ratio3.73 Quick Ratio3.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£6.39 million Price / Sales7.10 Cash FlowGBX 66.10 per share Price / Cash Flow2.16 Book ValueGBX 63.50 per share Price / Book2.24Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees62 Outstanding Shares31,833,800Market Cap£45.36 million Next Earnings DateN/A OptionableNot Optionable LSE:RENE Rates by TradingView Receive RENE News and Ratings via Email Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter. ReNeuron Group (LON:RENE) Frequently Asked Questions How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)? ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RENE shares have increased by 34.4% and is now trading at GBX 142.50. View which stocks have been most impacted by Coronavirus. How were ReNeuron Group's earnings last quarter? ReNeuron Group Plc (LON:RENE) released its quarterly earnings results on Friday, December, 6th. The company reported ($12.30) earnings per share for the quarter, topping analysts' consensus estimates of ($16.30) by $4.00. View ReNeuron Group's earnings history. Has ReNeuron Group been receiving favorable news coverage? Media coverage about RENE stock has trended somewhat positive on Friday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ReNeuron Group earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about ReNeuron Group. Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include Bellus Health (BLU), Burcon NutraScience (BU), Neuren Pharmaceuticals (NEU), IMV (IMV), Horizon Discovery Group (HZD), CorMedix (CRMD), OncoCyte (OCX), Resverlogix (RVX), Orgenesis (ORGS), Matinas Biopharma (MTNB), Predictive Technology Group (PRED), Monash IVF Group (MVF), Faron Pharmaceuticals Oy (FARN), BioTime (BTX) and Lineage Cell Therapeutics (LCTX). View all competitors. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF). Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the following people: Mr. Olav Hellebø, CEO & Director (Age 54)Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)Dr. Randolph Corteling, Head of ResearchMr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs What is ReNeuron Group's stock symbol? ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE." How do I buy shares of ReNeuron Group? Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ReNeuron Group's stock price today? One share of RENE stock can currently be purchased for approximately GBX 142.50. How big of a company is ReNeuron Group? ReNeuron Group has a market capitalization of £45.36 million and generates £6.39 million in revenue each year. ReNeuron Group employs 62 workers across the globe. What is ReNeuron Group's official website? The official website for ReNeuron Group is www.reneuron.com. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400. This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
